Literature DB >> 1067001

Oral corticosteroids in the treatment of ocular myasthenia gravis.

K C Fischer, R J Schwartzman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1067001     DOI： 10.1111/j.1749-6632.1976.tb47723.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Authors:  M J Kupersmith; G Ying
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

2.  Safety of prednisone for ocular myasthenia gravis.

Authors:  Beau B Bruce; Mark J Kupersmith
Journal:  J Neuroophthalmol       Date:  2012-09       Impact factor: 3.042

3.  Ocular Myasthenia Gravis.

Authors:  Victoria S. Pelak; Steven L. Galetta
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

4.  The ocular signs and symptoms of myasthenia gravis.

Authors:  H J Oosterhuis
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

5.  Myasthenia gravis: overlap with 'polyendocrine' autoimmunity.

Authors:  W A Scherbaum; F Schumm; B Maisch; C Müller; A Fateh-Moghadam; S H Flüchter; F J Seif; G F Bottazzo; P A Berg
Journal:  Klin Wochenschr       Date:  1983-05-16

6.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.